Perceptive Advisors LLC is a hedge fund that was founded in 1999 by Joseph Edelman. The firm invests in public equities globally by employing both short and long term investment strategies. According to the SEC 13F fillings for the third quarter ended September 30, 2014, the top three holdings of Perceptive Advisors LLC were Amicus Therapeutics Inc.(NASDAQ:FOLD), Neurocrine Biosciences Inc. (NASDAQ:NBIX), and Sarepta Therapeutics Inc.(NASDAQ:SRPT).
Amicus Therapeutics Inc. (NASDAQ:FOLD) was the topmost investment of Perceptive Advisors LLC with a total investment value of $73.4 million. Amicus Therapeutics Inc. (NASDAQ:FOLD) is a biopharmaceutical company that focuses on the development and marketing of therapies for rare and orphan diseases. Perceptive Advisors LLC was the top holder of the firm with shares totaling 12.3 million. Redmille Group came in the second position with 5.7 million shares. (You can see complete list of hedge funds which hold positions on Amicus Therapeutics Inc. (NASDAQ:FOLD) at the end of the third quarter.)
The second primary investment of Perceptive Advisors LLC was Neurocrine Biosciences Inc. (NASDAQ:NBIX) with a total investment value of $71.5 million. Neurocrine Biosciences Inc. (NASDAQ:NBIX) discovers and develops pharmaceuticals with a focus on endocrine and neurological diseases and disorders. The stock recently received a consensus rating of “buy” by analysts who are currently covering the stock. The top three shareholders of Neurocrine Biosciences Inc. (NASDAQ:NBIX) are Fidelity Management and Research Company, T. Rowe Price Associates, Inc., and Orbimed Advisors, LLC.
The third primary investment of Perceptive Advisors LLC was Sarepta Therapeutics Inc. (NASDAQ:SRPT) with investment worth $54.8 million. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a drug development and medical research company based in Massachusetts, USA. The company shares have been upgraded to a “strong buy” from a “buy” rating and given a price target of $25 by WBB Securities. This came after the company reported $0.70 earnings per share for the third quarter of 2014.
This article has been written by Victor Ochieng.
Related articles:
